MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
0.5770
-0.0246
-4.09%
Opening 12:23 09/28 EDT
OPEN
0.6000
PREV CLOSE
0.6016
HIGH
0.6000
LOW
0.5401
VOLUME
420.13K
TURNOVER
--
52 WEEK HIGH
15.75
52 WEEK LOW
0.1614
MARKET CAP
11.76M
P/E (TTM)
-0.0383
1D
5D
1M
3M
1Y
5Y
1D
Moleculin Advances Annamycin Following Peer-Reviewed Cardiac Safety Data
NASDAQ · 12h ago
Moleculin Reports Cardiac Safety Findings For Annamycin In Pooled Analysis
NASDAQ · 12h ago
Moleculin Highlights Annamycin Cardiac Safety in New Analysis
TipRanks · 12h ago
Moleculin Biotech announces publication of analysis of Annamycin in Frontiers
TipRanks · 12h ago
Weekly Report: what happened at MBRX last week (0921-0925)?
Weekly Report · 13h ago
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Barchart · 17h ago
Moleculin Highlights Immune-Driven Annamycin Pancreatic Cancer Data
TipRanks · 3d ago
Moleculin Biotech Announces Preclinical Data Showing Annamycin Antitumor Activity In Pancreatic Cancer Is Immune-Mediated
Benzinga · 3d ago
More
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.